John Glasspool Net Worth

John Glasspool biography

John Glasspool serves as Independent Director of the Company since December 19, 2019. Mr. Glasspool is also a member of the Company’s Compensation Committee and Chairman of the Company’s Corporate Governance and Nominating Committee. He has been CEO and member of the Board of Directors of Anthos Therapeutics since February 2019. He has been a member of the Board of Directors of Dalcor Corporation since May 2017, and a senior advisor to MIT since October 2016. From June 2017 to October 2018, he was a consultant for Roivant Sciences. From July 2015 to January 2017, Mr. Glasspool was the Executive Vice President, Head of Corporate Strategy and Customer Operations at Baxalta Incorporated, formerly Baxter BioScience. From August 2012 to June 2015, he was Vice President, Emerging Therapies and Market Development at Baxter Bioscience. Mr. Glasspool obtained a Bachelor of Arts degree from the University of Staffordshire and a degree in Business Administration from Oxford University. That Mr. Glasspool brings over 25 years of biotechnology experience to our Board of Directors, having served in various executive-level positions over the course of his career, and that Mr. Glasspool has developed significant management and leadership skills relating to the pharmaceutical industry led us to conclude that Mr. Glasspool should serve as a director.

How old is John Glasspool?

John Glasspool is 58, he's been the Independent Director of Relmada Therapeutics Inc since 2019. There are 10 older and 5 younger executives at Relmada Therapeutics Inc. The oldest executive at Relmada Therapeutics Inc is Charles Casamento, 75, who is the Independent Chairman of the Board.

What's John Glasspool's mailing address?

John's mailing address filed with the SEC is C/O RELMADA THERAPEUTICS, INC., 2222 PONCE DE LEON BLVD, 3RD FLOOR, CORAL GABLES, FL, 33134.

Insiders trading at Relmada Therapeutics Inc

Over the last 6 years, insiders at Relmada Therapeutics Inc have traded over $1,379,052 worth of Relmada Therapeutics Inc stock and bought 574,305 units worth $1,722,071 . The most active insiders traders include Sergio Traversa, Charles J Casamento et Paul Edward Kelly. On average, Relmada Therapeutics Inc executives and independent directors trade stock every 34 days with the average trade being worth of $54,221. The most recent stock trade was executed by Sergio Traversa on 9 September 2024, trading 140,000 units of RLMD stock currently worth $394,800.

What does Relmada Therapeutics Inc do?

relmada therapeutics (otcqb: rlmd) is a clinical-stage, publicly traded specialty pharmaceutical company developing novel versions of proven drug products together with new chemical entities that potentially address areas of high unmet medical need in the treatment of chronic pain. relmada has a diversified portfolio of four lead products at various stages of development including d-methadone (rel-1017) its n-methyl-d-aspartate (nmda) receptor antagonist for neuropathic pain; topical mepivacaine (rel-1021), its orphan drug designated topical formulation of the local anesthetic mepivacaine; oral buprenorphine (rel-1028) its oral dosage form of the opioid analgesic buprenorphine; and levocap er (rel-1015), its abuse resistant, sustained release dosage form of the opioid analgesic levorphanol. relmada’s product development efforts are guided by the internationally recognized scientific expertise of our research team. relmada’s approach is expected to reduce clinical development risks and

Relmada Therapeutics Inc executives and stock owners

Relmada Therapeutics Inc executives and other stock owners filed with the SEC include:

• Sergio Traversa,
  Chief Executive Officer, Director
• Dr. Sergio Traversa M.B.A., MBA, Pharm.D., PharmD,
  CEO & Director
• Dr. Sergio Traversa M.B.A., Pharm.D., PharmD, MBA,
  CEO & Director
• Maged S. Shenouda M.B.A., MBA, R.Ph, R.Ph.,
  Chief Financial Officer
• Charles Casamento,
  Independent Chairman of the Board
• Paul Kelly,
  Independent Director
• Maged Shenouda,
  Chief Financial Officer
• Charles S. Ence CPA, M.B.A.,
  Chief Accounting & Compliance Officer
• Maged S. Shenouda M.B.A., R.Ph., R.Ph, MBA,
  Chief Financial Officer
• Andrew Ipsum,
  IR Contact Officer
• Eric Schmidt,
  Independent Director
• John Glasspool,
  Independent Director
• Marco Pappagallo,
  Acting Chief Medical Officer
• Paolo Manfredi,
  Acting Chief Scientific Officer
• Charles Ence,
  Chief Accounting Officer, Chief Compliance Officer
• Marc de Somer,
  Senior Vice President - Clinical Development
• Thomas Wessel,
  Executive Vice President, Head of Research and Development
• John Hixon,
  Head of Commercial
• Dr. Richard M. Mangano,
  Consultant
• Dr. Marco Pappagallo M.D.,
  Chief Medical Officer
• Dr. Marc de Somer M.B.A., M.D., M.P.H., M.Sc.,
  Sr. VP of Clinical Devel.
• Gina DiGuglielmo,
  VP & Head of Clinical Operations
• Dr. Paolo Manfredi M.D., Ph.D.,
  Chief Scientific Officer
• Molly Harper,
  Exec. VP of Operations
• Fabiana Fedeli,
  Director
• Ottavio V. Vitolo,
  Chief Medical Officer
• Chuck Ence,
  CA and CO